Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

By Meghan Kelly · December 15, 2020, 5:46 PM EST

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

2:17-md-02785

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Case Title

KPH Healthcare Services, Inc. v. Mylan N.V. et al

Case Number

2:20-cv-02065

Court

Kansas

Nature of Suit

Anti-Trust

Date Filed

February 14, 2020

Featured Stories

Big Pharma Touts US Investments Amid Tariff Threat No Photo Available

Yeji Jesse Lee

As tariffs loom on the horizon, Big Pharma companies laud their plans to ramp up U.S. manufacturing — even as they're set to eat costs... (more story)

FDA Drug Rules Under Fire in Pharma Free Speech Fight No Photo Available

Hannah Albarazi

Vanda Pharmaceuticals says it spent years establishing that one of its flagship, FDA-approved products is an effective and safe treatm... (more story)

Legislation Roundup: States Consider Slew Of Abortion Bills No Photo Available

Mark Payne

Nearly three years after the U.S. Supreme Court's Dobbs decision upended federal abortion access protection, dozens of abortion-relate... (more story)